Lucid Diagnostics (LUCD) EBITDA (2020 - 2026)

Lucid Diagnostics has reported EBITDA for 7 years, with the latest figure at -$12.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 2.99% year-over-year to -$12.1 million; the trailing twelve-month figure through Mar 2026 stood at -$11.8 million (up 75.27% YoY), and the FY2025 full-year result was -$12.2 million, up 73.55% from the prior year.
• EBITDA for Q1 2026 stood at -$12.1 million, down from $23.4 million in the prior quarter.
• The five-year high for EBITDA was $23.4 million in Q4 2025, with the low at -$15.0 million in Q4 2022.
• Historically, EBITDA has averaged -$10.3 million across 5 years, with a median of -$11.8 million in 2025.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 235.92% — and 2025, when it soared 289.47%.
• Lucid Diagnostics' EBITDA stood at -$15.0 million in 2022, then gained by 23.52% to -$11.5 million in 2023, then declined by 8.05% to -$12.4 million in 2024, then soared by 289.47% to $23.4 million in 2025, then plunged by 151.67% to -$12.1 million in 2026.
• The last three EBITDA figures came in at -$12.1 million (Q1 2026), $23.4 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.